Preparation and coating of finely dispersed drugs 4. Loratadine and danazol

Sreco D Skapin; Srečo D. Škapin; Egon Matijević

doi:10.1016/j.jcis.2003.08.035

Preparation and coating of finely dispersed drugs 4. Loratadine and danazol

Sreco D Skapin, Srečo D. Škapin, Egon Matijević

Journal of colloid and interface science · 2003 · vol. 272(1) , pp. 90–98 · doi:10.1016/j.jcis.2003.08.035 · PMID:14985026 · W46803622

Other OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This paper describes the preparation and coating of finely dispersed drugs.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The preparation of colloidal particles of different morphologies, including spheres, of two drugs, loratadine and danazol, is described. In principle these particles were obtained by precipitation when nonsolvents (water or aqueous surfactant solutions) were added to ethanol solutions of the drug. In addition, procedures were developed that made it possible to use the drug particles thus obtained as cores to be then coated with either silica or aluminum (hydrous) oxide layers. The presence of these inorganic shells was confirmed by electron microscopy, energy dispersive spectroscopy, and electrophoresis.

My notes (saved in your browser only)

MeSH descriptors

Chemistry, Pharmaceutical Danazol Loratadine Danazol Loratadine Microscopy, Electron, Scanning Models, Molecular Molecular Conformation

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs 1995

References (16)

Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
doi:10.1006/jcis.2001.8137 via openalex
doi:10.1557/jmr.1994.0436 via openalex
doi:10.1006/jcis.1998.5730 via openalex
doi:10.1021/cen-v081n008.p032 via openalex
doi:10.1016/0378-5173(95)00148-c via openalex
doi:10.1006/jcis.2000.7012 via openalex
doi:10.1021/la00013a003 via openalex
doi:10.1006/jcis.1999.6106 via openalex
doi:10.1007/bf02111396 via openalex
doi:10.1021/j100725a052 via openalex
doi:10.1016/0095-8522(64)90035-2 via openalex
doi:10.1016/0021-9797(92)90229-f via openalex
doi:10.1006/jcis.2002.8408 via openalex
doi:10.1201/9781482294668 via openalex
doi:10.1557/jmr.1996.0396 via openalex

Source provenance

openalex: last seen: 2026-05-11T05:37:28.352103+00:00
pubmed: last seen: 2026-10-08T21:02:24.140261+00:00
unpaywall: last seen: 2026-10-28T06:33:34.531809+00:00

License: CC0 · commercial use OK

[1] Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs 1995